Skip to main content
Erschienen in: Endocrine Pathology 2/2022

Open Access 09.02.2022 | Metastasis

Tumor-to-Tumor Metastasis: Lung Typical Carcinoid Metastatic to Follicular Variant of Papillary Thyroid Carcinoma

verfasst von: Ugolini Clara, Del Frate Rossella, Rossi Giulio, Materazzi Gabriele, LiVolsi Virginia

Erschienen in: Endocrine Pathology | Ausgabe 2/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original online version of this article was revised: Fig. 1 caption was incorrect.
A correction to this article is available online at https://​doi.​org/​10.​1007/​s12022-022-09717-1.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Case Presentation

In August 2020, a 70-year-old man presented with a rapidly growing nodule of the left thyroid lobe and was referred for a total thyroidectomy.
The histological examination revealed a neoplasm with two different admixed components: an encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) and a more internal component with neuroendocrine appearance. The FVPTC showed follicular growth and characteristic nuclear features of papillary carcinoma. The neuroendocrine component demonstrated uniform cells, with elongated shapes and finely granular chromatin, inconspicuous nucleoli, and a moderate amount of cytoplasm; it had a solid and trabecular growth pattern. Both the components showed tumoral capule infiltrations. Immunostaining showed that the neuroendocrine component stained for chromogranin A. Conversely, thyroglobulin, TTF-1, and PAX-8 were positive in the papillary carcinoma component (Fig. 1). Morphological and immunophenotypical evidence pointed to a neuroendocrine neoplasm which metastasized to FVPTC.
At this time, the clinical history of the patient became known to us. In 2007, the patient was diagnosed with a peripheral typical lung carcinoid (LC). In January 2010, he underwent a laminectomy D5-D6, revealing a metastatic pulmonary neuroendocrine tumor (NET).

Discussion

Metastases to the thyroid gland are rare events. The most frequent tumor metastasis to the thyroid is carcinomas of the kidney, lung, colon and breast, and melanoma while malignancies from other sites rarely involve the gland [1, 2].
A rarer event involves the presence of tumor-to-tumor metastasis in the thyroid. Strict criteria are required to accept such a case: the recipient tumor must be a true neoplasm, and the donor tumor must be a tumor metastasis (direct contiguous spreading is not sufficient to define a tumor-to-tumor metastasis) [3].
Prior reports have described neuroendocrine tumors metastasizing into the thyroid gland. The first article was possibly reported by Laguette et al. who reported six cases, the majority of which derived from primaries in the lung, while only one possessing the morphological features of a typical carcinoid [4]. In 1999, Baloch et al. described three neuroendocrine tumors metastasizing into FVPTC, with primaries from lung, pancreas, and kidney [5].
In general, reported cases of lung NETs metastatic to the thyroid have been of intermediate-grade NETs (“atypical carcinoid”) or neuroendocrine carcinomas. Specifically, the combination of marked nuclear atypia, high mitotic rate, and necrosis was the criterion used to categorize the cases as atypical carcinoid tumors.
In these cases, selective studies of immunohistochemical markers, including thyroid markers, such as thyroglobulin and TTF-1, and molecular markers are necessary for differential diagnosis. Primary thyroid tumors with neuroendocrine features including MTC or mixed medullary-papillary carcinomas need to be considered and excluded.
Our case showed positive expression for thyroglobulin and TTF-1 in the papillary component while the LC component showed positive expression for chromogranin A and negativity for TTF-1, thyroglobulin, PAX-8, m-CEA, and calcitonin. This immunohistochemical pattern excluded both MTC and mixed thyroid carcinoma.
To further support our hypothesis, we have separately investigated the mutational status of HRAS proto-oncogene, GTPase (HRAS), KRAS proto-oncogene, GTPase (KRAS), NRAS proto-oncogene, GTPase (NRAS) and B-Raf proto-oncogene, and serine/threonine kinase (BRAF) genes with different techniques. The FVPTC was positive for the mutation c.181C > A (p.Q61K) in HRAS gene, whereas sequencing analysis of the neuroendocrine component did not reveal any mutation.
In summary, this case shows an occurrence of tumor-to-tumor metastasis of a typical carcinoid of the lung involving a FVPTC. Although exceedingly rare, secondary tumors of the thyroid gland should always be especially considered in the clinical setting of a previous malignancy.

Declarations

Conflict of interests

The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

Literatur
Metadaten
Titel
Tumor-to-Tumor Metastasis: Lung Typical Carcinoid Metastatic to Follicular Variant of Papillary Thyroid Carcinoma
verfasst von
Ugolini Clara
Del Frate Rossella
Rossi Giulio
Materazzi Gabriele
LiVolsi Virginia
Publikationsdatum
09.02.2022
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 2/2022
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-022-09706-4

Weitere Artikel der Ausgabe 2/2022

Endocrine Pathology 2/2022 Zur Ausgabe

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …